The therapeutic application of siRNA (short interfering RNA) shows promise as an alternative approach to small-molecule inhibitors for the treatment of human disease. However, the major obstacle to its use has been the difficulty in delivering these large anionic molecules in vivo. A potential approach to solving this problem is the chemical conjugation of siRNA to the cationic CPPs (cell-penetrating peptides), Tat-(48-60) (transactivator of transcription) and penetratin, which have been shown previously to mediate protein and peptide delivery in a host of animal models. In this transaction, we review recent studies on the utility of siRNA for the investigation of protein function in the airways/lung. We show that, despite previous studies showing the utility of cationic CPPs in vitro, conjugation of siRNA to Tat-(48-60) and penetratin failed to increase residual siRNA-mediated knockdown of p38 MAPK (mitogen-activated protein kinase) (MAPK14) mRNA in mouse lung in vivo. Significantly, we will also discuss potential non-specific actions and the induction of immunological responses by CPPs and their conjugates and how this might limit their application for siRNA-mediated delivery in vivo.
Introduction
The knockdown of protein expression using siRNA (short interfering RNA)-mediated RNAi (RNA interference) is now commonly used to investigate the function of genes during biological responses [1, 2] . Furthermore, this strategy is currently being examined for the treatment of diseases such as macular degeneration, hepatitis C infection and cancer [3] [4] [5] [6] . However, owing to its relatively large size and anionic charge, one of the key problems in utilizing siRNA as a therapeutic agent, and during studies in vivo, is the availability of effective delivery systems. Initial investigations suggest that siRNA delivery may only be possible in cells/ tissues that are amenable to topical applications such as the eye and the vagina or, largely due to the first-pass effect, it is possible to target the liver following intravenous administration.
The structure of the lung permits direct access to the branching airways and alveoli and therefore might represent an ideal organ for application of siRNA-based therapeutics. Indeed, this contention is supported by studies showing safe and efficacious siRNA-mediated modulation of a range of diseases in animal models, including acute lung injury, bleomycin-induced fibrosis and allergen-induced airway hyperresponsiveness (Table 1 ). These actions have been mediated through down-regulation of a variety of targets Abbreviations used: CPP, cell-penetrating peptide; IL, interleukin; i.n., intranasal; i.t., intratracheal; KC, keratinocyte-derived cytokine; MAPK, mitogen-activated protein kinase; MIP, macrophage inflammatory protein; SARS, severe acute respiratory syndrome; siRNA, short interfering RNA; Tat, transactivator of transcription; TLR, Toll-like receptor; TNFα, tumour necrosis factor α. 1 To whom correspondence should be addressed (email m.lindsay@imperial.ac.uk).
including haem oxygenase [7, 8] , discoidin domain receptor [9] , IL (interleukin)-13 receptor [10] , Fas [11] , caspase 8 [11] , MIP (macrophage inflammatory protein)-2 [12] , KC (keratinocyte-derived cytokine) [12] , caveolin-1 [13] and arginase I [14] . Interestingly, siRNAs have also been shown to effectively reduce viral titre and symptoms in mice infected with influenza, para-influenza and respiratory syncytial virus following the targeting of viral proteins [15] [16] [17] [18] . Furthermore, Li et al. [19] have demonstrated siRNA-mediated attenuation of SARS (severe acute respiratory syndrome) following coronavirus infection in rhesus macaques using either a prophylactic or therapeutic regime.
In the majority of these studies, siRNA was administered either via the i.n. (intranasal) or the i.t. (intratracheal) route packaged in cationic lipids (e.g. Oligofectamine TM ) and polymers (e.g. polyethyleneimine and dendrimers). However, such siRNA formulation approaches suffer drawbacks including toxicity and siRNA-mediated induction of immune responses through TLRs (Toll-like receptors) [20] [21] [22] . To address these problems, we and others have investigated the effect of chemical conjugation to the CPPs (cell-penetrating peptides) penetratin and Tat-(48-60) (transactivator of transcription) upon siRNA delivery in vitro and in vivo. The CPPs Tat-(48-60) and penetratin are short cationic peptide sequences derived from the HIV-1 Tat [23, 24] and the insect Antennapedia homeoprotein (penetratin) [25] respectively. Both have been extensively evaluated for the in vitro and in vivo delivery of biologically active peptides and proteins [26, 27] . Significantly, CPPs have been shown to mediate uptake of a range of other biological and non-biological cargoes, which has led to the suggestion that they might represent a universal non-toxic approach for the delivery of oligonucleotides [28] [29] [30] [31] . 
In vitro siRNA delivery and CPPs
A number of investigators have demonstrated penetratinmediated delivery of siRNA and antisense oligonucleotides into isolated neurons [32] [33] [34] and knockdown of eGFP (enhanced green fluorescent protein) and CDK9 (cyclindependent kinase 9) expression in HeLa cells using siRNA conjugated to Tat-(48-60) [35] , with biological activity reported at the sub-micromolar range. In all these studies, the CPP was linked to the siRNA via a disulfide bond; in the case of penetratin, this was to the 5 -end of the sense strand [32] [33] [34] , whereas Chiu et al. [35] attached the Tat-(48-60) residue to the 3 -end of the antisense strand.
In vivo lung siRNA delivery and CPPs
In the absence of reports on Tat-(48-60)-or penetratinmediated siRNA delivery in vivo, we investigated the utility of this approach in the mouse lung. Specifically, we targeted p38 MAPK (mitogen-activated protein kinase) (also known as MAPK14), whose activation is known to be important in the release of multiple pro-inflammatory mediators including TNFα (tumour necrosis factor α) and IL-1 [36, 37] . In these studies, we used a commercially available siRNA sequence (Dharmacon) which we found to exert potent p38 MAPK knockdown when transfected into mouse fibrobasts (L929) in culture (IC 50 ∼140 pM).
We conjugated Tat and penetratin to the 5 -end of the sense strand via a disulfide linkage between a cysteine residue on the peptide and a C 6 -thiol linker on the oligonucleotides, followed by denaturing HPLC purification, and showed a limited shift in IC 50 to ∼800 pM. In the absence of transfection, unconjugated siRNA failed to show p38 MAPK knockdown in vitro across the concentrations evaluated (0.3-10 µM). In contrast, both the Tat-(48-60)-and penetratinsiRNA conjugates, but not CPP alone, achieved an ∼40% down-regulation at the highest concentration, without loss of cell viability. However, these micromolar concentrations were significantly higher than those reported previously to give biological activity using CPP-siRNA conjugates in vitro [32] [33] [34] [35] . Although we are uncertain of the reason for these differences, these investigators do not appear to have carried out post-conjugation HPLC purification in the presence of denaturing agents in order to remove excess cationic CPP from the siRNA-peptide conjugate. Thus, as with nonconjugated cationic lipids and polymers, increased delivery could have resulted from the formation of complexes [38] .
To determine their biological activity in vivo, we administered siRNA duplexes into mice by i.t. instillation under mild anaesthesia. As reported previously with unmodified non-formulated siRNA [7, 9, 11, 12] , we observed a significant down-regulation of p38 MAPK expression using non-conjugated C 6 -thiol linker-modified siRNA alone penetratin peptide and siRNA conjugated to either Tat-(48-60) (TAT-siRNA) or penetratin (penetratin-siRNA) upon MAPK14 mRNA expression in mouse lung, 6 h after i.t. administration. Results are means ± S.E.M., n = 6-18 animals per group. Samples were analysed using Student's t test. *P < 0.05 compared with PBS-treated controls.
( Figure 1 ). This is despite the fact that siRNAs have been shown to be degraded rapidly in serum by enzymes such as RNase A [39] and implies that lung provides a more tolerant environment. Administration of the CPP-siRNA failed to show an effect of conjugation to Tat-(48-60) or penetratin upon either the distribution, magnitude or duration of lung p38 MAPK knockdown (Figure 1) . In surprising contrast with our in vitro observations, penetratin peptide alone induced a significant knockdown in p38 MAPK mRNA expression 6 h after administration and, in the case of Tat-(48-60), this was also observed at 12 and 24 h (results not shown), suggesting a non-selective action of these peptides upon gene expression. The mechanism and extent of this phenomenon is still unclear; however, in the absence of adverse behaviour or gross histological changes at 24 h following administration, lung toxicity in the form of necrosis or apoptosis can be eliminated. Indeed, exposure of the lung epithelial A549 cell line to Tat-(48-60) or penetratin at concentrations of up to 30 µM does not induce toxicity [40] . Alternatively, the observed reduction in expression of p38 MAPK mRNA could occur following the non-specific interaction of CPPs with extracellular or intracellular targets. In this respect, both CPPs in our study have been reported to induce clathrin-dependent uptake of the TNFα and EGF (epidermal growth factor) receptors, without their activation [41] . Additionally, as these highly positively charged CPPs are major constituents of transcription factor DNA-binding domains, interference with gene transcription could account for our observations. Interestingly, this tight binding to both plasma membranes and genomic DNA has been shown previously to result in erroneous conclusions about the mechanism of CPP uptake [42, 43] .
Notwithstanding these non-selective actions of Tat-(48-60) and penetratin, we have additionally observed the elicitation of an innate immune response by the penetratinsiRNA, but not the Tat-(48-60)-siRNA conjugate or the siRNA alone (Figure 2 ). On the basis of the cytokine profile documented, this response could be a result of the
Figure 2 Effects of various siRNAs and CPPs on pro-inflammatory cytokine levels in mouse lung
Effects of MAPK14 siRNA, 4-base mismatch siRNA, Tat-(48-60) peptide, penetratin peptide and siRNA conjugated to either Tat-(48-60) (TAT-siRNA) or penetratin (penetratin-siRNA) upon pro-inflammatory cytokine levels in the mouse lung 6 h after i.t. administration. Results are means ± S.E.M., n = 5-6 animals per group. Samples were analysed using the one-way ANOVA and Tukey post-analysis. *P < 0.05; ***P < 0.001 compared with PBS-treated controls. IFN, interferon; ND, not determined because of lack of sample. activation of TLR-3, -7 and/or TLR-8 in the endosomal pathway [44] . As siRNA, Tat-(48-60) peptide or penetratin peptide alone did not have an impact upon inflammatory biomarker levels, we believe that the mechanics of penetratin-mediated siRNA delivery might differ from that of the Tat-(48-60) conjugate.
Overall, these studies and those of other investigators suggest that the airways and lung are an ideal target for siRNA-based therapeutics. Thus even unmodified and nonformulated siRNA produce protein knockdown following i.t. and i.n. delivery. Under these circumstances, it may not be surprising that conjugation to CPPs such as Tat-(48-60) and penetratin were unable to increase knockdown of p38 MAPK mRNA expression, although this approach may be beneficial for delivery in other systems. However, our results imply that, when using Tat-(48-60) and penetratin as a delivery vehicle, it will be important to consider non-specific actions of these CPPs, as well as the possible induction of immunological responses by the penetratin-siRNA conjugates. 
